EU approves AZ’ potassium binder for hyperkalaemia
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
Read More
Tag: ZS-9
Second US rejection for AZ’ potassium binder
AstraZeneca’s hyperkalaemia treatment ZS-9 has suffered another setback on the path to US approval having been rejected by regulators for the second time. The drug giant also unveiled a US-based partnership with Circassia for development and commercialisation of COPD drugs Turdoza and Duaklir.
Read More
Six new medicines endorsed for EU approval
Six new medicines, including the first hormone replacement therapy for a thyroid disorder, have been put forward for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
FDA accepts resubmission of AZ’ potassium-binder
US regulators have accepted AstraZeneca unit ZS Pharma’s resubmission of ZS-9, a potassium-binding compound being developed for hyperkalaemia.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
